12-WEEK INTERFERON-FREE REGIMEN OF ABT-450/R +ABT-333+RIBAVIRIN ACHIEVED SVR12 IN MORE THAN 90% OF TREATMENT-NAIVE HCV GENOTYPE-1-INFECTED SUBJECTS AND 47% OF PREVIOUS NON-RESPONDERS

被引：42
|
作者：
Poordad, F. [1 ]
Lawitz, E. [2 ]
Kowdley, K. V. [3 ]
Everson, G. T. [4 ]
Freilich, B. [5 ]
Cohen, D. [6 ]
Siggelkow, S. [6 ]
Heckaman, M. [6 ]
Menon, R. [6 ]
Pilot-Matias, T. [6 ]
Podsadecki, T. [6 ]
Bernstein, B. [6 ]
机构：
[1] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[2] Alamo Med Res, San Antonio, TX USA
[3] Virginia Mason Med Ctr, Digest Dis Inst, Seattle, WA 98101 USA
[4] Univ Colorado Denver & Hosp, Aurora, CO USA
[5] Kansas City Gastroenterol & Hepatol, Kansas City, MO USA
[6] Abbott, Abbott Pk, IL USA
来源：
JOURNAL OF HEPATOLOGY | 2012年 / 56卷
关键词：
D O I：
10.1016/S0168-8278(12)61410-X
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1399
引用
收藏
页码：S549 / S550
页数：2
相关论文
共 34 条
  • [11] SVR12 Rate of 95.7% in 209 HCV Genotype 1-Infected Null Responders Treated With ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
    Jacobson, Ira M.
    DuFour, Jean-Francois J.
    Enejosa, Jeffrey
    de Knegt, Robert J.
    Ferenci, Peter
    Reynaert, Hendrik
    Di Bisceglie, Adrian M.
    Larsen, Lois
    Baykal, Tolga
    Rodrigues-, Lino, Jr.
    Podsadecki, Thomas
    Jensen, Donald M.
    Poordad, Fred
    HEPATOLOGY, 2014, 60 : 1133A - 1133A
  • [12] ABT-072 OR ABT-333 COMBINED WITH PEGYLATED INTERFERON/RIBAVIRIN AFTER 3-DAY MONOTHERAPY IN HCV GENOTYPE 1 (GT1)-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK SUSTAINED VIROLOGIC RESPONSE (SVR12) AND SAFETY RESULTS
    Poordad, F.
    Lawitz, E.
    DeJesus, E.
    Kowdley, K. V.
    Gaultier, I.
    Cohen, D. E.
    Xie, W.
    Larsen, L.
    Pilot-Matias, T.
    Koev, G.
    Dumas, E.
    Podsadecki, T.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2012, 56 : S478 - S478
  • [13] Low Relapse Rate Leads to High Concordance of SVR4 and SVR12 with SVR24 After Treatment with ABT-450/r, ABT-267, ABT-333+Ribavirin in Patients with Chronic HCV Genotype 1 Infection in the AVIATOR Study
    Poordad, Fred
    Agarwal, Kosh
    Younes, Ziad
    Cohen, Daniel E.
    Xie, Wangang
    Podsadecki, Thomas
    HEPATOLOGY, 2013, 58 : 735A - 736A
  • [14] ABT-450/RITONAVIR (ABT-450/R) COMBINED WITH PEGYLATED INTERFERON ALPHA-2A AND RIBAVIRIN (SOC) AFTER 3-DAY MONOTHERAPY IN GENOTYPE 1 HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12-WEEK INTERIM EFFICACY AND SAFETY RESULTS
    Lawitz, E.
    Gaultier, I.
    Poordad, F.
    Cohen, D. E.
    Menon, R.
    Larsen, L. M.
    Podsadecki, T.
    Bernstein, B.
    JOURNAL OF HEPATOLOGY, 2011, 54 : S482 - S482
  • [15] RESULTS OF THE PHASE 2 STUDY M12-999: INTERFERON-FREE REGIMEN OF ABT-450/R/ABT-267+ABT-333+RIBAVIRIN IN LIVER TRANSPLANT RECIPIENTS WITH RECURRENT HCV GENOTYPE 1 INFECTION
    Kwo, P.
    Mantry, P.
    Coakley, E.
    Te, H.
    Vargas, H.
    Brown, R., Jr.
    Gordon, F.
    Levitsky, J.
    Terrault, N.
    Burton, J., Jr.
    Xie, W.
    Setze, C.
    Badri, P.
    Vilchez, R. A.
    Forns, X.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S47 - S48
  • [16] SAPPHIRE II: PHASE 3 PLACEBO-CONTROLLED STUDY OF INTERFERON-FREE, 12-WEEK REGIMEN OF ABT-450/R/ABT-267, ABT-333, AND RIBAVIRIN IN TREATMENT-EXPERIENCED ADULTS WITH HEPATITIS C VIRUS GENOTYPE 1
    不详
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S1 - S1
  • [17] PEARL-II: Randomized Phase 3 Trial of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333 With or Without Ribavirin in Hepatitis C Virus Genotype 1b-Infected, Treatment-Experienced Patients
    Andreone, Pietro
    Colombo, Massimo
    Enejosa, Jeffrey V.
    Koksal, Iftihar
    Ferenci, Peter
    Maieron, Andreas
    Muellhaupt, Beat
    Horsmans, Yves
    Weiland, Ola
    Reesink, Henk W.
    Rodrigues, Lino, Jr.
    Hu, Yiran B.
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2014, 146 (05) : S159 - S159
  • [18] SAPPHIRE II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week Regimen of ABT-450/r/ABT-267, ABT-333, and Ribavirin in 394 Treatment-Experienced Adults With Hepatitis C Virus Genotype 1
    Jacobson, Ira M.
    Zeuzem, Stefan
    Baykal, Tolga
    Marinho, Rui T.
    Poordad, Fred
    Bourliere, Marc
    Sulkowski, Mark
    Wedemeyer, Heiner
    Tam, Edward
    Desmond, Paul V.
    Jensen, Donald M.
    Di Bisceglie, Adrian M.
    Varunok, Peter
    Hassanein, Tarek
    Xiong, Junyuan
    DaSilva-Tillmann, Barbara
    Larsen, Lois
    Podsadecki, Thomas
    GASTROENTEROLOGY, 2014, 146 (05) : S904 - S904
  • [19] SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin
    Colombo, Massimo
    Weiland, Ola
    Cohen, Daniel E.
    DuFour, Jean-Francois J.
    Reynaert, Hendrik
    Diago, Moises
    Villa, Erica
    Streinu-Cercel, Adrian
    Xie, Wangang
    Baykal, Tolga
    Enejosa, Jeffrey
    Coakley, Eoin
    Trinh, Roger
    Podsadecki, Thomas
    HEPATOLOGY, 2014, 60 : 1131A - 1131A
  • [20] EXPOSURE-RESPONSE ANALYSES FOR EFFICACY (SVR12) FOR THE DIRECT ACTING ANTIVIRAL REGIMEN OF ABT-450/R, OMBITASVIR WITH DASABUVIR plus /- RIBAVIRIN IN SUBJECTS WITH HCV GENOTYPE 1 INFECTION
    Khatri, A.
    Mensing, S.
    Podsadecki, T.
    Awni, W.
    Menon, R.
    Dutta, S.
    JOURNAL OF HEPATOLOGY, 2015, 62 : S682 - S682
1234